Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
PER-001 by Perfuse Therapeutics for Diabetic Retinopathy: Likelihood of Approval
PER-001 is under clinical development by Perfuse Therapeutics and currently in Phase II for Diabetic Retinopathy. According to GlobalData, Phase...